Print this page
-
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Heptocellular Carcinoma and CHILDPUGH B7 and B8 Cirrhosis.
Protocol: 072309Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Liver -
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Prostate
Rectum
Small Intestine -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy.
Protocol: 072311Principal Investigator:
- Sharon Li
Applicable Disease Sites: Liver -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers.
Protocol: 072401Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Other Digestive Organ -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas -
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer.
Protocol: 072407Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Anus -
A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula.
Protocol: 072501Applicable Disease Sites: Pancreas
-
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of
Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab
as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Protocol: 072502Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Liver -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
Individual Patient Expanded Access of CTX-009 for the treatment of metastatic gallbladder cancer
Protocol: 072506Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Other Digestive Organ -
ScreenNJ Resource and Evaluation Unit
Protocol: 131820Applicable Disease Sites: Colon
Lung -
Practices, knowledge and beliefs of colorectal cancer patients and their providers prescription practices regarding anemia and oral iron supplementation
Protocol: 132003Principal Investigator:
- Carolyn J Heckman
Applicable Disease Sites: Colon
Rectum -
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST).
Protocol: 132307Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Other Female Genital
Ovary
Pancreas
Prostate -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
PIONEER (Preparing for Implementation and Optimization of aNal scrEEning and tReatment)
Protocol: 132311Principal Investigator:
- Racquel Kohler
Applicable Disease Sites: Anus